CN1923191B - Use of flavanone kind composition in preparation of medicine for curing cardio vascular diseases - Google Patents
Use of flavanone kind composition in preparation of medicine for curing cardio vascular diseases Download PDFInfo
- Publication number
- CN1923191B CN1923191B CN2005100936436A CN200510093643A CN1923191B CN 1923191 B CN1923191 B CN 1923191B CN 2005100936436 A CN2005100936436 A CN 2005100936436A CN 200510093643 A CN200510093643 A CN 200510093643A CN 1923191 B CN1923191 B CN 1923191B
- Authority
- CN
- China
- Prior art keywords
- blu
- formula
- flavanone
- preparation
- kind composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 239000000203 mixture Substances 0.000 title claims description 29
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 title claims description 22
- 229930003949 flavanone Natural products 0.000 title claims description 22
- 235000011981 flavanones Nutrition 0.000 title claims description 22
- 238000002360 preparation method Methods 0.000 title claims description 22
- 150000002207 flavanone derivatives Chemical class 0.000 title claims 6
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 241000196324 Embryophyta Species 0.000 claims description 9
- 208000031225 myocardial ischemia Diseases 0.000 claims description 9
- 240000000572 Blumea balsamifera Species 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 238000011287 therapeutic dose Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 26
- 150000002208 flavanones Chemical class 0.000 description 15
- -1 lactone compound Chemical class 0.000 description 13
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 229930003944 flavone Natural products 0.000 description 9
- 235000011949 flavones Nutrition 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- YEYLMQKEGSQNGZ-AWEZNQCLSA-N Blumeatin Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)OC)=CC(O)=CC(O)=C1 YEYLMQKEGSQNGZ-AWEZNQCLSA-N 0.000 description 8
- YEYLMQKEGSQNGZ-UHFFFAOYSA-N Blumeatin Natural products O1C2=CC(OC)=CC(O)=C2C(=O)CC1C1=CC(O)=CC(O)=C1 YEYLMQKEGSQNGZ-UHFFFAOYSA-N 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 6
- SVPNMFZMHPLGRR-UHFFFAOYSA-N 3,3',5-Trihydroxy-4',7-dimethoxyflavanone Chemical compound O1C2=CC(OC)=CC(O)=C2C(=O)C(O)C1C1=CC=C(OC)C(O)=C1 SVPNMFZMHPLGRR-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012567 medical material Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 201000005577 familial hyperlipidemia Diseases 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 3
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 240000004460 Tanacetum coccineum Species 0.000 description 3
- 206010053615 Thermal burn Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000008384 feverfew Nutrition 0.000 description 3
- 150000002213 flavones Chemical class 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 3
- 229940033663 thimerosal Drugs 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000002026 chloroform extract Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- 238000003810 ethyl acetate extraction Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 229940023488 pill Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241001252601 Blumea Species 0.000 description 1
- 206010005963 Bone formation increased Diseases 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- DCTLJGWMHPGCOS-UHFFFAOYSA-N Osajin Chemical compound C1=2C=CC(C)(C)OC=2C(CC=C(C)C)=C(O)C(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DCTLJGWMHPGCOS-UHFFFAOYSA-N 0.000 description 1
- OUZCFMSJGDEXRT-UHFFFAOYSA-N Scandinone Natural products O=C1C=2C(OC)=C(CC=C(C)C)C=3OC(C)(C)C=CC=3C=2OC=C1C1=CC=C(O)C=C1 OUZCFMSJGDEXRT-UHFFFAOYSA-N 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 229930015036 aurone Natural products 0.000 description 1
- 150000001530 aurones Chemical class 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 229930192579 blumealactone Natural products 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 150000001789 chalcones Chemical class 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000011987 flavanols Nutrition 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 208000014221 sudden cardiac arrest Diseases 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses the use of dihydroflavonoids compounds having general formula (I) in preparing medicament for preventing and treating cardiovascular diseases, wherein R1 is H or CH3, R2 is H or CH3, R3 is H or OH. The invention also relates to the pharmaceutical compositions containing the dihydroflavonoids compounds, wherein the content of the dihydroflavonoids compounds in each unit of the dose is 5-1000mg.
Description
Technical field
The present invention relates to flavanone kind composition and treat and/or prevent the application in the cardiovascular disease medicine in preparation.
The invention still further relates to the pharmaceutical composition that comprises said flavanone kind composition.
Background technology
Herba Blumeae Balsamiferae (Blumea balsamifera (L.) DC) is a feverfew, has another name called Balsamiferou Blumea Herb, Da Ai, sees to be stated from " Guangxi Chinese crude drug standard " (nineteen ninety version).Herba Blumeae Balsamiferae medical material main uses is to extract Borneolum Syntheticum (Borneol), also has minority Chinese medicine compound recipe to be used as medicine with this medical material or its volatile oil.
The preparation that is used as medicine with Herba Blumeae Balsamiferae extract in the prior art, its reactive compound are mainly the Oleum Blumeae Balsamiferae that composition is a terpene substances, like " the upright refreshing drop pill of pharynx ", Jinjian larynx spray, the mould peace Oral preparation of match etc.The bibliographical information relevant with Herba Blumeae Balsamiferae relates generally to plant culture, plant component etc., and pharmaceutical research relates generally to the liver protective effect.The disclosed Chinese patent relevant with Herba Blumeae Balsamiferae extract relates generally to laryngopharyngeal diseases, skin scald, gynaecopathia, as, 200410034599 (promoting blood flow and remove blood stasis and stop bleeding regulating menoxenias); 200410013042,200410013040,200410013041,200410013039,200410016005,03124605,03124594 (gynaecopathia); (97107723.1 treatment oral cavity and laryngopharyngeal diseases), 98112092.X (treatment laryngopharyngeal diseases), 94102037.1 (specially controlling various skin scalds and many places dermatopathy); (951100521.9 treatment hyperosteogeny disease); Other has the disclosed Chinese patent of part to relate to the compound Chinese medicinal preparation of being used as medicine with Herba Blumeae Balsamiferae, as 94114866.1 (treatment burn, scald) etc.In addition, Japan Patent JP62087589 relates to three kinds of contained lactone compound Blumealactones A of Herba Blumeae Balsamiferae, B, C.
The application of Herba Blumeae Balsamiferae total flavones extract in preparation resisting myocardial ischemia and blood lipid-lowering medicine disclosed in the one Chinese patent application 02134927.4 (CN1403451A); But described Herba Blumeae Balsamiferae total flavones extract is an effective ingredient in Chinese; Only be as main component (or main functional component) with flavone compound; It is the combination of multiple composition; And said flavone compound is meant and belongs to flavonoid, flavonols, flavanone, flavanone alcohols, anthocyan, flavanol compound, two benzene pyrrones on the structure; The chemical compound of osajin, chalcones, dihydrochalcone-type, aurones class, homoisoflavone class etc., and they and monosaccharide or the oligosaccharide glucosides or the other forms of derivant that form, and; The gross weight sum of flavone compound accounts for 25～100% of extract gross weight; Is this on earth effect to be produced or the generation of multiple chemical compound by certain chemical compound so the application of the disclosed Herba Blumeae Balsamiferae total flavones extract of this patent in preparation resisting myocardial ischemia and blood lipid-lowering medicine is the common effect of multiple flavone extract? Which kind of therapeutical effect does each monomer all have? Be still waiting further investigation.
The present invention has furtherd investigate the flavanone kind composition that from Herba Blumeae Balsamiferae, extracts and has treated and/or prevented the application in the cardiovascular disease medicine in preparation.
Summary of the invention
One object of the present invention is to provide the flavanone kind composition suc as formula shown in (I) to treat and/or prevent the application in the cardiovascular disease medicine in preparation, and this compounds can separate from the plant Herba Blumeae Balsamiferae and obtains.
Also purpose of the present invention is to provide the pharmaceutical composition that comprises said flavanone kind composition.
According to an aspect of the present invention, described its structure of flavanone kind composition is shown in general formula (I):
Wherein, R
1Be H or CH
3
R
2Be H or CH
3
R
3Be H or OH.
Above-mentioned formula (I) chemical compound can separate from the plant Herba Blumeae Balsamiferae and obtains, and " Herba Blumeae Balsamiferae " according to the invention is meant feverfew Herba Blumeae Balsamiferae (Blumea balsamifera (L.) DC) plant, and the preferred aerial parts of its plant is like dry stem and leaf.
In the chemical compound shown in the above-mentioned general formula (I), the R in formula (I)
1Be H, R
2Be CH
3, R
3During for OH, the chemical name of said chemical compound is 3,3 '; 5,7-tetrahydroxy-4 '-methoxyl group-flavanone (3,3 '; 5; 7-tetrahydroxy-4 '-methoxy-flavanone), with its called after blumeatin A (its English name " blumeatin A " or its English initialism " Blu A "), its structure is suc as formula shown in (II) in the present invention:
R in formula (I)
1And R
2Be CH
3, R
3During for OH, the chemical name of said chemical compound is 3,3 '; 5-trihydroxy-4 ', 7-dimethoxy-flavanone (3,3 '; 5-tetrahydroxy-4 '; 7-dimethoxy-flavanone), with its called after blumeatin B (its English name " blumeatin B " or its English initialism " Blu B "), its structure is suc as formula shown in (III) in the present invention:
R in formula (I)
1Be CH
3, R
2Be H, R
3During for H; The chemical name of said chemical compound is 3 ', 4 ', 5-trihydroxy-7-methoxyl group-flavanone (3; 4 '; 5-tetrahydroxy-7-dimethoxy-flavanone), with its called after Herba Blumeae Balsamiferae third element (its English name " blumeatin C " or its English initialism " Blu C "), its structure is suc as formula shown in (IV) in the present invention:
Flavanone kind composition shown in the above-mentioned general formula (I) can separate acquisition through conventional plant Chemical Decomposition purification technique known in the art from the plant Herba Blumeae Balsamiferae.Those skilled in that art can understand, and these chemical compounds also can obtain through the method for chemosynthesis.
In a specific embodiment of the present invention, the method for preparing of said flavanone kind composition comprises the steps:
A, Herba Blumeae Balsamiferae is dry, pulverizing are used alcohol reflux, obtain ethanol extract;
B, with ethanol extract in order with chloroform and ethyl acetate extraction, obtain chloroform extract and ethyl acetate extract;
C, step B is extract obtained through silica gel chromatographic column chromatography repeatedly separates obtaining the flavanone kind composition shown in the general formula (I).
Said cardiovascular disease mainly comprises and myocardial ischemia and dyslipidemia diseases associated, for example myocardial infarction, angina pectoris, hypertension, arteriosclerosis, hyperlipemia and coronary heart disease etc.
Said coronary heart disease is the abbreviation of coronary atherosclerotic heart disease, also claims ischemic heart desease.Clinical symptoms comprises angina pectoris, arrhythmia, acute myocardial infarction, heart failure and sudden cardiac arrest (sudden death) etc.
Said hyperlipemia comprises former or the hyperlipemia concurrent with other disease.
Pharmacodynamics test shows: the flavanone kind composition shown in the formula (I) has good resisting myocardial ischemia and transfers blood fat; And has the pharmacodynamics synergism between them.
According to also aspect of the present invention, the invention provides a kind of pharmaceutical composition that is used to treat or prevent human diseases, it comprises flavanone kind composition and pharmaceutically acceptable carrier and/or the excipient shown in the general formula (I) of effective therapeutic dose.
Said " effectively therapeutic dose " is meant under this dosage, flavanone kind composition according to the invention can improve or palliate a disease symptom, or can suppress or block disease progression.
Pharmaceutical composition according to the invention can be a drug-delivery preparation in the gastrointestinal tract, like oral Preparation etc.Wherein, oral solid formulation can be tablet, capsule, granule, pill, lozenge etc.In these preparations, except that the active component that comprises the present invention, can also choose wantonly and contain pharmaceutically acceptable filler, fluidizer, lubricant, correctives, coloring agent etc.These preparations can also be prepared into slow release or controlled release preparation as required.Oral liquid can be solution, suspension, emulsion, elixir etc.Drug-delivery preparation can also be Sublingual tablet, suppository etc. in the gastrointestinal tract.
The present composition can be the parenteral preparation.These preparations can be solution, suspension, emulsion etc.They can pass through intravenous, subcutaneous, intramuscular administration.
For oral formulations such as tablet, the capsule etc. of the present composition, in active component, the dosage of flavone compound described in its unit dosage forms can be 5～1000mg.Preferably, the dosage of flavone compound described in its unit dosage forms is 30～500mg.It can be administered once and/or several every day, each administration a slice (grain) and/or several pieces (grain).
Compared with prior art, the present invention finds that first the flavanone kind composition monomer has good resisting myocardial ischemia and effect for reducing blood fat, can be used for treating and/or preventing of cardiovascular disease such as coronary heart disease, hyperlipemia, atherosclerosis.
In order to understand essence of the present invention better,, specify but do not limit the present invention below through to the description of preferred embodiments of the present invention.
The specific embodiment of invention
The used Herba Blumeae Balsamiferae medical material of the present invention is purchased in medical material company, through being accredited as the dry stem and leaf of feverfew Herba Blumeae Balsamiferae (Blumea balsamifera (L.) DC).Adjuvant that the present invention is used and reagent are commercially available purchase commodity like no specified otherwise.
The separation and the evaluation of blumeatin A, second element, third element
[embodiment 1]
1, extract and separate:
Herba Blumeae Balsamiferae medical material (dry stem and leaf) 500g, pulverizing, 70% alcohol reflux (7.5L * 2), merge extractive liquid, in order with chloroform and ethyl acetate extraction, reclaims solvent, and is extract obtained through silica gel chromatographic column chromatography repeatedly.As a result, from ethyl acetate extract, separate obtaining compound I I, III, from chloroform extract, separate obtaining compound I I, IV.
2, identify:
Chemical compound 1 (blumeatin A, Blu A): white needle.
Elementary analysis: elementary analysis, C:58.18%; H:5.22% does not contain N, S, X.Empirical formula C
16H
14O
7(theoretical value C:58.28%; H:5.18%; O:36.54%), degree of unsaturation 9.
IR：3451；3413(υO-H，s)，2944；2838(υC-H，m)，1649；1634(υC＝O，s)，1361(υC-OH，m)，1259(υC-O-C，s)，1161，1138(υC-H，s)，1086(υC-OH，s)，1027，997，975(δC-H，s)，839，836，798(δC-H，m)，811(δC-H，m)，766(δC-H，m).
UV-VIS: with ethanol, 0.1mol/L NaOH, three kinds of solvent preparations of 0.1mol/L HCl sample solution.Determination data is as shown in table 1.
The ultraviolet spectra of table 1 chemical compound 1
1H-NMR：3.78(3H，s)，4.51-4.54(1H，m，)，5.03(1H，d，11.2Hz)，5.81(1H，d，6.2Hz)，5.87(1H，d，1.9Hz)，5.92(1H，d，1.9Hz)，6.87(1H，d，8.0Hz)，6.47(1H，d，7.0Hz)，6.94(1H，s)，9.08(1，s)，10.85(1，s)，11.95(1，s)；
13C-NMR：71.56(C-3)，82.83(C-2)，95.02(C-6)，96.02(C-8)，100.50(C-4)，111.71(C-5’)，115.10(C-6’)，119.26(C-2’)，129.73(C-1’)，146.20(C-3’)，147.98(C-4’)，162.52(C-7)，163.34(C-9)，166.83(C-5)，197.78(C-4)。
MS：317(M+1)。
Identify that according to above data this chemical compound is 3,3 ', 5,7-tetrahydroxy-4 '-methoxyl group-flavanone.With its called after blumeatin A (Blumeatin A, Blu A).Its structural formula is:
Chemical compound 2 (blumeatin B, Blu B): white needle-like crystals.
m.p.：180～182℃；
EI-MS：333(M+1)；
UV(CH
3OH，λmax，nm)：289；
1H?NMR(DMSO，δ)：11.82(1H，s，C5-OH)；8.91(1H，s，C3’-OH)；9.23(1H，s，C3’-OH)；6.92(1H，s，C2’)；6.91(1H，d，J＝8Hz，C6’)；6.88(1H，d，J＝8Hz，C5’-H)；6.09(1H，d，J＝2Hz，C8-H)；6.06(1H，d，J＝2Hz，C6-H)；5.74(1H，d，J＝2Hz，3-OH)；5.06(1H，dd，J＝11Hz，J＝2Hz，C3-OH)；4.52(1H，d，J＝11Hz，C3-H)3.78(6H，S，2×OCH
3)。
Identify that according to above data this chemical compound is 3,3 ', 5-trihydroxy-4 ', 7-methoxyl group-flavanone, the present invention is called blumeatin B (Blumeatin B, Blu B).Its structural formula is:
Chemical compound 3 (Herba Blumeae Balsamiferae third element, Blu C): white needle-like crystals.
m.p.：218℃；
EI-MS：303(M+1)；
UV(CH
3OH，λmax，nm)：289；
1H?NMR(DMSO，δ)：12.08(1H，s，C5-OH)；8.97(1H，s，C4’-OH)；8.91(1H，s，C3’-OH)；6.88(1H，s，C2’-H)；6.74(2H，s，C5’-H，6’-H)；6.06(2H，s，C6-H，C8-H)；5.43(1H，dd，J＝12.5，4Hz，C2-H)；3.78(3H，s，OCH
3)；3.20(1H，dd，J＝17.5，12.5Hz，C3-H)；2.71(1H，dd，J＝17.5，4Hz，C3-H)。
Identify that according to above data this chemical compound is 3 ', 4 ', 5-trihydroxy-7-methoxyl group-flavanone, the present invention is called Herba Blumeae Balsamiferae third element (Blumeatin C, Blu C).Its structural formula is:
Pharmacodynamic experiment
[embodiment 2] Blu A, B, C are to the influence of rat heart muscle ischemia due to the coronary ligation
1, test material:
1) test specimen
Blu A, Blu B, Blu C: spectroscopic pure, all by the method separation and purification of embodiment 1 from the Herba Blumeae Balsamiferae medical material.
2) experimental animal
SD rat: purchase in Guangdong Medical Lab Animal Center
2, test method:
The SD rat, gastric infusion is 3 days continuously, twice of every day.Experiment is divided into groups and each treated animal dosage is seen table 7.NS is a normal saline.30min after the last administration with Animal Anesthesia, opens breast knot and pricks coronary artery left side descending branch, record II lead electrocardiogram.It is dirty to core after 2 hours, and the myocardial infarction area size is observed in dyeing.
3, result of the test:
(1) Blu A, B, C are to the Electrocardiographic influence of coronary ligation rat
The result is as shown in table 2.Experimental result shows: Blu A, B, C all have and suppress the effect that the rat ECG ST section raises due to the coronary ligation, explain that these test specimens all have myocardial ischemia effect due to the anti-coronary ligation.
Different time points ECG ST section current potential (mV behind the table 2 rat coronary ligation; N=6, X ± SD)
*P＜0.05,
*P＜0.01 sampling test group and NS group be (t-test) relatively.
(2) Blu A, B, C are to the influence of coronary ligation rat heart muscle infarcted region area
The result is as shown in table 3.Experimental result shows: Blu A, B, C all significantly reduce ischemic necrosis district area, confirm that further these test specimens all have function of resisting myocardial ischemia; Aspect efficacy strength, its strong and weak order with above-mentioned to the Electrocardiographic basically identical that influences, that is, and Blu A, B, C.
The myocardial infarction region area was than (n=6, X ± SD)
after table 3 was respectively organized the rat coronary artery ligation
*(t-test) compared with the NS group in p＜0.01
[embodiment 3] Blu A, B, C are to the regulating action of unusual blood fat
1, test material:
Test specimen and experimental animal and source thereof are with embodiment 2.
2, experimental technique:
The SD rat feeds 1 week of normal diet under experimental situation, and the blood sampling of the eye corner of the eyes is surveyed blood fat as normal value.The normal control group is fed normal diet, and high fat matched group is fed high lipid food, and experimental group is fed high lipid food administration simultaneously, and administration is plucked eyeball after 2 weeks and got blood, measures each item index.
3, experimental result:
The influence of rat hyperlipidemia is as shown in table 4 due to Blu A, B, the C high lipid food.Experimental result shows: Blu A, B, C all have certain accent blood fat.
Table 4 rat high blood lipid model is respectively organized blood fat reducing experimental result (n=10)
*P＜0.05,
*P＜0.01 sampling test group and blank group be (t-test) relatively
The preparation of drug combination that contains Blu A, B, C
Raw material sources:
Blu A, Blu B, Blu C: spectroscopic pure, all separate purification from the Herba Blumeae Balsamiferae medical material.
The preparation of [embodiment 4] tablet
I, prescription:
Principal agent 60g
Starch 50g
Dextrin 60g
Sucrose 10g
Magnesium stearate 2g
Process 1000
Annotate: the principal agent in the prescription is Blu A or Blu B or Blu C
II, method for making: Blu A or Blu B or Blu C sieve with suitable medicine sieve and mix until the mixture that forms homogeneous with sucrose, starch.Add an amount of water and powder is granulated.After the drying, with this granule sieve and with all the other mixed with excipients.Then the gained granule is pressed into the tablet of required form.The tablet of other content can prepare through ratio or the tabletting weight that changes reactive compound and excipient.
The preparation of [embodiment 5] capsule
I, prescription:
Principal agent 60g
Lactose 60g
Dextrin 15g
Starch (120 order) 45g
3%HPMC is an amount of
Process 1000
Annotate: the principal agent in the prescription is Blu A or Blu B or Blu C
II, method for making: Blu A or Blu B or Blu C cross 80 mesh sieves, with starch, lactose, dextrin by equivalent multiplication method mix homogeneously, add the HPMC solution for preparing in advance and process soft material, 20 mesh sieves are granulated, about 30 minutes of 60 ℃ of dryings, 18 mesh sieve granulate, encapsulated.
The preparation of [embodiment 6] injection
I, prescription:
Principal agent 25g
Thimerosal 0.01g
Tween 80 1.5g
Sodium chloride 3g
Sodium carboxymethyl cellulose (30-60cpas) 5g
Water for injection adds to 1000ml
Annotate: the principal agent in the prescription is Blu A or Blu B or Blu C
II, method for making: thimerosal is added in the water for injection of 50% amount, adds sodium carboxymethyl cellulose, and the dissolving back filters with 200 order nylon wires, and is airtight subsequent use.Sodium chloride is dissolved in an amount of water for injection, after No. 4 sintered filter funnel filters, adds preheating thimerosal solution and tween 80 and stirs, and heating makes boiling; Add BluA or BluB or BluC, mixing takes out and is chilled to room temperature, adds the injection water and transfers to cumulative volume; Sintered filter funnel filters, packing (5ml/ props up), sterilization.
Above detailed description of the present invention does not limit the present invention, and those skilled in the art can make various changes and distortion according to the present invention, only otherwise break away from spirit of the present invention, all should belong to the defined scope of accompanying claims of the present invention.
Claims (8)
1. the application of the flavanone kind composition shown in the formula (I) in the preparation medicaments for resisting myocardial ischemia
Wherein, R
1Be H or CH
3
R
2Be H or CH
3
R
3Be H or OH.
2. application as claimed in claim 1 is characterized in that the R in the formula (I)
1Be H, R
2Be CH
3, R
3Be OH; Structure is suc as formula shown in (II):
3. application as claimed in claim 1 is characterized in that the R in the formula (I)
1And R
2Be CH
3, R
3Be OH; Structure is suc as formula shown in (III):
4. application as claimed in claim 1 is characterized in that the R in the formula (I)
1Be CH
3, R
2Be H, R
3Be H; Structure is suc as formula shown in (IV):
5. application as claimed in claim 1 is characterized in that said flavanone kind composition separates to obtain from plant Herba Blumeae Balsamiferae (Blumea balsamifera (L.) DC).
6. a pharmaceutical composition that is used for resisting myocardial ischemia is characterized in that comprising
Flavanone kind composition shown in the formula (I) of effective therapeutic dose; And
Pharmaceutically acceptable carrier and/or excipient;
Wherein, R
1Be H or CH
3
R
2Be H or CH
3
R
3Be H or OH.。
7. the described pharmaceutical composition of claim 6, the dosage that it is characterized in that flavanone kind composition described in its unit dosage forms is 5～1000mg.
8. the described pharmaceutical composition of claim 7, the dosage that it is characterized in that flavanone kind composition described in its unit dosage forms is 30～500mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005100936436A CN1923191B (en) | 2005-08-31 | 2005-08-31 | Use of flavanone kind composition in preparation of medicine for curing cardio vascular diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005100936436A CN1923191B (en) | 2005-08-31 | 2005-08-31 | Use of flavanone kind composition in preparation of medicine for curing cardio vascular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1923191A CN1923191A (en) | 2007-03-07 |
| CN1923191B true CN1923191B (en) | 2012-07-18 |
Family
ID=37816134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2005100936436A Expired - Fee Related CN1923191B (en) | 2005-08-31 | 2005-08-31 | Use of flavanone kind composition in preparation of medicine for curing cardio vascular diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1923191B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102973552B (en) * | 2012-12-06 | 2015-04-01 | 北京中医药大学 | Application of blumea balsamifera |
| CN107515259B (en) * | 2017-08-03 | 2020-04-21 | 深圳海王医药科技研究院有限公司 | Method for determining blumea balsamifera element content in blumea balsamifera ketone tablets |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1125637C (en) * | 2000-07-19 | 2003-10-29 | 中山大学 | Application of 5,3',5'-trihydroxy-methoxyl dihydroflavone in preparing medicine |
-
2005
- 2005-08-31 CN CN2005100936436A patent/CN1923191B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1125637C (en) * | 2000-07-19 | 2003-10-29 | 中山大学 | Application of 5,3',5'-trihydroxy-methoxyl dihydroflavone in preparing medicine |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1923191A (en) | 2007-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6153198A (en) | Withania somnifera composition | |
| CN1398838A (en) | Diphenylethylene compound and its prepn and application in preventing and treating diabetes | |
| WO2006034655A1 (en) | Steroidal saponin pharmaceutical composition, its preparation method and use | |
| CN102526165A (en) | Rhodiola effective fractions, preparation method, drug composition and uses thereof | |
| WO1993002684A1 (en) | β-GLUCURONIDASE INHIBITOR | |
| CN102228506A (en) | Composition of malaytea scurfpea extract as well as preparation method and use thereof | |
| CN104910240B (en) | Triterpenoid saponin in Bougainvillea glabra, the hypoglycemic drug with it as active component, and its preparation method and application | |
| WO2006063515A1 (en) | Use of radix sanguisorbae and its extract for preparing medicament to increase rbc and hemoglobin | |
| JP6389958B2 (en) | Medicinal use of anti-tumor for rutile pentacyclic triterpene saponins | |
| CN103880856B (en) | Bisabolane sesquiterpene derivant and pharmaceutical composition thereof and its application in pharmacy | |
| CN1294912A (en) | Blood sugar reducing compound | |
| CN107746403B (en) | Serial ring-opening abietane diterpenoid compounds, pharmaceutical compositions thereof and application thereof in pharmacy | |
| CN101423537A (en) | Scutellarin and medical use thereof | |
| CN1923191B (en) | Use of flavanone kind composition in preparation of medicine for curing cardio vascular diseases | |
| CN101899041A (en) | Superior medicinal crystal-form solid substance of puerarin as well as preparation method and application thereof | |
| CN106074588A (en) | The combination of Rhizoma Paridis forrestii monomer saponin and pharmaceutical composition and its application in pharmacy | |
| CN101974011B (en) | New compound methyl brevicate with medical activity | |
| CN100467025C (en) | Use of asiaticoside in preparation of medicines for diseases of cardio-cerebral blood vessels | |
| CN103110680A (en) | Preparation method of total phenolic acid of erigeron breviscapus | |
| CN101974012B (en) | Novel compound ethyl brevicate with pharmaceutical activity | |
| CN106554349A (en) | Wild anistree new isopentene group replaces C6‑C3Class compound and preparation method thereof, application and its pharmaceutical composition | |
| KR100485936B1 (en) | Anticarcinogenic constituents of ginsenoside Rh2 and Rg3 | |
| CN115806490B (en) | Phenolic hetero-terpene compound with function of activating AMPK phosphorylation, pharmaceutical composition, preparation method and application | |
| CN101974010B (en) | New compound erigeron breviscapus acid with officinal activity | |
| CN102351874B (en) | New erigeroster compound with medicinal activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120718 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |